Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer

Figure 2 Residual not bevacizumab-bound vascular endothelial growth factor in plasma in function of time. Histograms represent the percentage of the ratio of not bevacizumab (BV)-bound vascular endothelial growth factor (VEGF) to total VEGF in plasma before the 2^nd and the 5^th cycle of therapy, respectively. ^aP < 0.05, the 2^nd cycle vs the 5^th cycle.